Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.
F
F
Ostronoff
M
M
Othus
P A
PA
Ho
M
M
Kutny
D E
DE
Geraghty
S H
SH
Petersdorf
J E
JE
Godwin
C L
CL
Willman
J P
JP
Radich
F R
FR
Appelbaum
D L
DL
Stirewalt
S
S
Meshinchi
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics*; D000090205:DNA Methyltransferase 3A; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005091:Exons / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009154:Mutation / Q000235:genetics*; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
C000717967:DNMT3A protein, human; D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone; D004248:DNA (Cytosine-5-)-Methyltransferases; D000090205:DNA Methyltransferase 3A; D003630:Daunorubicin